|Send to printer »|
GEN News Highlights : Sep 7, 2010
NIH to Dole Out More Than $161M Over Five Years to Bolster Pharmacogenomic Research
Awards will expand projects into new diseases like RA and bipolar disorder and fortify resources.!--h2>
NIH plans on spending $161.3 million over the next five years to expand the Pharmacogenomics Research Network (PGRN). The new awards include 14 scientific research projects and seven network resources.
The resources will offer deep DNA sequencing capacity, provide statistical analysis expertise, develop standardized terminology for pharmacogenomics research, pilot ways to learn about pharmacogenomics from de-identified medical records in healthcare systems, and expand a two-year-old international collaboration with the Center for Genomic Medicine at the RIKEN Institute in Yokohama, Japan.
Spearheaded by the NIH's National Institute of General Medical Sciences (NIGMS) and launched in 2000, the PGRN has linked gene variants to responses to medicines for different cancers, heart disease, asthma, nicotine addiction, and other conditions. The expanded network will continue research in these areas and move into new ones including rheumatoid arthritis and bipolar disorder. Network scientists will also develop novel research methods and study the use of pharmacogenetics in rural and underserved populations.
"Thanks to breakthroughs in genome-sequencing technologies and our growing understanding of genetic variation among individuals, there has never been a better time to propel the field of pharmacogenomics," comments NIH director Francis S. Collins, M.D., Ph.D. "Through these studies we are moving closer to the goal of using genetic information to help prescribe the safest, most effective medicine for each patient."
The lead investigators of the PGRN research groups receiving grants and anticipated five-year total costs are listed below:
The network resources and anticipated five-year total costs for each grant are listed below:
© 2013 Genetic Engineering & Biotechnology News, All Rights Reserved